bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2700
+0.0151 (5.92%)
At close: Sep 12, 2025, 4:00 PM EDT
0.3400
+0.0700 (25.93%)
After-hours: Sep 12, 2025, 7:59 PM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$134,755
Profits / Employee
-$205,069
Market Cap
7.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIAF News
- 5 days ago - Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules - Business Wire
- 27 days ago - bioAffinity Technologies Appoints New Members to Board of Directors - Business Wire
- 4 weeks ago - bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Business Wire
- 4 weeks ago - bioAffinity Technologies Reports Second Quarter 2025 Results - Business Wire
- 4 weeks ago - bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Business Wire
- 4 weeks ago - bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales - Business Wire
- 6 weeks ago - Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results - Business Wire
- 7 weeks ago - Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic - Business Wire